Cargando…

Feasibility study for detection of retinal amyloid in clinical trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial

INTRODUCTION: The retina and brain exhibit similar pathologies in patients diagnosed with neurodegenerative diseases. The ability to access the retina through imaging techniques opens the possibility for non‐invasive evaluation of Alzheimer's disease (AD) pathology. While retinal amyloid deposi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngolab, Jennifer, Donohue, Michael, Belsha, Alison, Salazar, Jennifer, Cohen, Paula, Jaiswal, Sandhya, Tan, Veasna, Gessert, Devon, Korouri, Shaina, Aggarwal, Neelum T., Alber, Jessica, Johnson, Ken, Jicha, Gregory, van Dyck, Christopher, Lah, James, Salloway, Stephen, Sperling, Reisa A., Aisen, Paul S., Rafii, Michael S., Rissman, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369843/
https://www.ncbi.nlm.nih.gov/pubmed/34430703
http://dx.doi.org/10.1002/dad2.12199
_version_ 1783739367609597952
author Ngolab, Jennifer
Donohue, Michael
Belsha, Alison
Salazar, Jennifer
Cohen, Paula
Jaiswal, Sandhya
Tan, Veasna
Gessert, Devon
Korouri, Shaina
Aggarwal, Neelum T.
Alber, Jessica
Johnson, Ken
Jicha, Gregory
van Dyck, Christopher
Lah, James
Salloway, Stephen
Sperling, Reisa A.
Aisen, Paul S.
Rafii, Michael S.
Rissman, Robert A.
author_facet Ngolab, Jennifer
Donohue, Michael
Belsha, Alison
Salazar, Jennifer
Cohen, Paula
Jaiswal, Sandhya
Tan, Veasna
Gessert, Devon
Korouri, Shaina
Aggarwal, Neelum T.
Alber, Jessica
Johnson, Ken
Jicha, Gregory
van Dyck, Christopher
Lah, James
Salloway, Stephen
Sperling, Reisa A.
Aisen, Paul S.
Rafii, Michael S.
Rissman, Robert A.
author_sort Ngolab, Jennifer
collection PubMed
description INTRODUCTION: The retina and brain exhibit similar pathologies in patients diagnosed with neurodegenerative diseases. The ability to access the retina through imaging techniques opens the possibility for non‐invasive evaluation of Alzheimer's disease (AD) pathology. While retinal amyloid deposits are detected in individuals clinically diagnosed with AD, studies including preclinical individuals are lacking, limiting assessment of the feasibility of retinal imaging as a biomarker for early‐stage AD risk detection. METHODS: In this small cross‐sectional study we compare retinal and cerebral amyloid in clinically normal individuals who screened positive for high amyloid levels through positron emission tomography (PET) from the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial as well as a companion cohort of individuals who exhibited low levels of amyloid PET in the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) study. We quantified the number of curcumin‐positive fluorescent retinal spots from a small subset of participants from both studies to determine retinal amyloid deposition at baseline. RESULTS: The four participants from the A4 trial showed a greater number of retinal spots compared to the four participants from the LEARN study. We observed a positive correlation between retinal spots and brain amyloid, as measured by the standardized uptake value ratio (SUVr). DISCUSSION: The results of this small pilot study support the use of retinal fundus imaging for detecting amyloid deposition that is correlated with brain amyloid PET SUVr. A larger sample size will be necessary to fully ascertain the relationship between amyloid PET and retinal amyloid both cross‐sectionally and longitudinally.
format Online
Article
Text
id pubmed-8369843
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83698432021-08-23 Feasibility study for detection of retinal amyloid in clinical trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial Ngolab, Jennifer Donohue, Michael Belsha, Alison Salazar, Jennifer Cohen, Paula Jaiswal, Sandhya Tan, Veasna Gessert, Devon Korouri, Shaina Aggarwal, Neelum T. Alber, Jessica Johnson, Ken Jicha, Gregory van Dyck, Christopher Lah, James Salloway, Stephen Sperling, Reisa A. Aisen, Paul S. Rafii, Michael S. Rissman, Robert A. Alzheimers Dement (Amst) Retinal Imaging INTRODUCTION: The retina and brain exhibit similar pathologies in patients diagnosed with neurodegenerative diseases. The ability to access the retina through imaging techniques opens the possibility for non‐invasive evaluation of Alzheimer's disease (AD) pathology. While retinal amyloid deposits are detected in individuals clinically diagnosed with AD, studies including preclinical individuals are lacking, limiting assessment of the feasibility of retinal imaging as a biomarker for early‐stage AD risk detection. METHODS: In this small cross‐sectional study we compare retinal and cerebral amyloid in clinically normal individuals who screened positive for high amyloid levels through positron emission tomography (PET) from the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial as well as a companion cohort of individuals who exhibited low levels of amyloid PET in the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) study. We quantified the number of curcumin‐positive fluorescent retinal spots from a small subset of participants from both studies to determine retinal amyloid deposition at baseline. RESULTS: The four participants from the A4 trial showed a greater number of retinal spots compared to the four participants from the LEARN study. We observed a positive correlation between retinal spots and brain amyloid, as measured by the standardized uptake value ratio (SUVr). DISCUSSION: The results of this small pilot study support the use of retinal fundus imaging for detecting amyloid deposition that is correlated with brain amyloid PET SUVr. A larger sample size will be necessary to fully ascertain the relationship between amyloid PET and retinal amyloid both cross‐sectionally and longitudinally. John Wiley and Sons Inc. 2021-08-17 /pmc/articles/PMC8369843/ /pubmed/34430703 http://dx.doi.org/10.1002/dad2.12199 Text en © 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Retinal Imaging
Ngolab, Jennifer
Donohue, Michael
Belsha, Alison
Salazar, Jennifer
Cohen, Paula
Jaiswal, Sandhya
Tan, Veasna
Gessert, Devon
Korouri, Shaina
Aggarwal, Neelum T.
Alber, Jessica
Johnson, Ken
Jicha, Gregory
van Dyck, Christopher
Lah, James
Salloway, Stephen
Sperling, Reisa A.
Aisen, Paul S.
Rafii, Michael S.
Rissman, Robert A.
Feasibility study for detection of retinal amyloid in clinical trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial
title Feasibility study for detection of retinal amyloid in clinical trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial
title_full Feasibility study for detection of retinal amyloid in clinical trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial
title_fullStr Feasibility study for detection of retinal amyloid in clinical trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial
title_full_unstemmed Feasibility study for detection of retinal amyloid in clinical trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial
title_short Feasibility study for detection of retinal amyloid in clinical trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial
title_sort feasibility study for detection of retinal amyloid in clinical trials: the anti‐amyloid treatment in asymptomatic alzheimer's disease (a4) trial
topic Retinal Imaging
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369843/
https://www.ncbi.nlm.nih.gov/pubmed/34430703
http://dx.doi.org/10.1002/dad2.12199
work_keys_str_mv AT ngolabjennifer feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT donohuemichael feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT belshaalison feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT salazarjennifer feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT cohenpaula feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT jaiswalsandhya feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT tanveasna feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT gessertdevon feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT korourishaina feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT aggarwalneelumt feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT alberjessica feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT johnsonken feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT jichagregory feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT vandyckchristopher feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT lahjames feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT sallowaystephen feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT sperlingreisaa feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT aisenpauls feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT rafiimichaels feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial
AT rissmanroberta feasibilitystudyfordetectionofretinalamyloidinclinicaltrialstheantiamyloidtreatmentinasymptomaticalzheimersdiseasea4trial